Medico Remedies Ltd. (MEDICO) AI Stock Analysis

Medico Remedies Ltd.

(NSE:MEDICO)

Select Model

Rating:65Neutral

Price Target:INR 20.00▲(5.99% Upside)

Action:reiterated

Date:09/29/26

Strong financial performance from revenue and earnings growth plus balance sheet stability is the main positive factor. Weak technical signals from price action below moving averages and negative MACD weigh on the score, while fair valuation provides modest support.

Positive Factors

Consistent Revenue GrowthSustained revenue expansion indicates strengthening demand and market reach rather than dependence on a single isolated period. The FY2026 acceleration provides a durable growth base that can support operating scale, reinvestment, and continued improvement in earnings over the next several quarters.

Negative Factors

Weak Cash ConversionThe divergence between rising profits and sharply weaker operating cash flow raises concern about earnings quality and working-capital intensity. Negative free cash flow can restrict internally funded growth and may increase reliance on borrowing or other financing if weak conversion persists.

Medico Remedies Ltd. (MEDICO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 1.82B
Dividend Yield: ―
Average Volume (3M): 29.73K
Price to Earnings (P/E): 11.1
Beta (1Y): 0.35
Revenue Growth: 49.96%
EPS Growth: 33.70%
Country: India
Employees: 105
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Medico Remedies Ltd. Business Overview & Revenue Model

Company Description

Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. Its product portfolio includes general formulations, which consists of general tablets, capsules, and dry syrups; and beta lactum formulations, which co...

Medico Remedies Ltd. Financial Statement Overview

Summary

Strong revenue and net income growth with solid balance sheet expansion and manageable debt levels. Cash flow volatility and occasional negative free cash flow remain key risks.

Income Statement

82Very Positive

Balance Sheet

78Positive

Cash Flow

62Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	2.38B	2.06B	1.51B	1.45B	1.40B	1.21B
Gross Profit	496.22M	445.57M	426.11M	175.25M	355.66M	176.65M
EBITDA	221.00M	229.60M	150.03M	148.57M	135.66M	74.34M
Net Income	138.15M	131.15M	100.93M	82.91M	72.42M	48.12M
Balance Sheet
Total Assets	0	1.53B	1.20B	961.95M	874.48M	774.04M
Cash, Cash Equivalents and Short-Term Investments	37.51M	37.51M	25.45M	15.46M	21.95M	23.40M
Total Debt	0	192.04M	147.00M	80.50M	97.62M	125.97M
Total Liabilities	-754.75M	779.29M	573.30M	438.24M	436.05M	408.30M
Stockholders Equity	754.75M	754.75M	624.69M	523.71M	438.43M	373.20M
Cash Flow
Free Cash Flow	-5.86M	-34.84M	17.07M	2.04M	15.75M	-11.50M
Operating Cash Flow	6.43M	10.06M	48.92M	24.38M	81.67M	58.62M
Investing Cash Flow	-12.01M	-46.47M	-34.60M	-26.77M	-66.03M	-17.56M
Financing Cash Flow	-2.70M	44.53M	-5.20M	-4.90M	-18.17M	-57.71M

Medico Remedies Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price18.87

Price Trends

50DMA30.38Negative

100DMA36.38Negative

200DMA40.10Negative

Market Momentum

MACD-3.03Negative

RSI18.17Positive

STOCH6.34Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Negative. The current price of 18.87 is below the 20-day moving average (MA) of 21.21, below the 50-day MA of 30.38, and below the 200-day MA of 40.10, indicating a bearish trend. The MACD of -3.03 indicates Negative momentum. The RSI at 18.17 is Positive, neither overbought nor oversold. The STOCH value of 6.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICO.

Medico Remedies Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:MEDICO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:MEDICO	65Neutral	INR 1.55B	11.14	―	―	49.96%	33.70%
IN:ZIMLAB	60Neutral	INR 7.32B	166.21	―	―	7.55%	-57.19%
IN:MEDICAMEQ	59Neutral	INR 3.47B	31.98	―	0.39%	24.66%	10.89%
IN:VALIANTLAB	59Neutral	INR 6.95B	43.52	―	―	89.64%	10627.64%
IN:BAFNAPH	58Neutral	INR 10.60B	136.14	―	―	-3.14%	-5.80%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ALBERTDAVD	54Neutral	INR 4.35B	19.29	―	0.65%	11.43%	258.53%

* General Sector Average

Performance Comparison

IN:MEDICO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:MEDICO	Medico Remedies Ltd.	18.65	-31.30	-62.66%
IN:ALBERTDAVD	Albert David Ltd	762.90	-114.67	-13.07%
IN:BAFNAPH	Bafna Pharmaceuticals Limited	447.90	285.75	176.23%
IN:MEDICAMEQ	Medicamen Biotech Limited	255.50	-120.56	-32.06%
IN:VALIANTLAB	Valiant Laboratories Ltd.	127.90	44.90	54.10%
IN:ZIMLAB	Zim Laboratories Ltd.	136.45	63.40	86.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 29, 2026

Medico Remedies Ltd. AI Stock Analysis